Workshop Series

Medlior and MORSE Consulting are pleased to offer a workshop dedicated to the reimbursement considerations for drugs for rare disease indications.

The workshop will be tailored for market access teams working on rare disease assets to understand the fundamentals of outcomes-based agreements (OBAs) and steps in generating real-world evidence (RWE) to support these agreements.

The specific topics for the workshop include:

• Navigating the Landscape: Understanding possibilities for OBAs in rare diseases and characteristics of a product and therapeutic area best suited for successful OBAs in Canada
• Data-Driven Success: How to assess your RWE needs for HTA and negotiations
• Canadian Requirements: Identifying Canadian RWE sources, processes, and requirements for accessing and generating necessary data
• Strategic Planning: Building an RWE strategy that serves multiple purposes across market access
• Leveraging Patient Support Programs: Effective strategies for partnership and success

The 2-hour workshops will be held virtually and led by senior staff from MORSE and Medlior. All participants will receive a comprehensive PDF of the workshop content, as well as Q&A notes that could serve as a future reference.

Contact us at for more information on pricing and availability.

• Tara Cowling, President and Managing Principal, Medlior
• Suzanne McMullen, Senior Principal, Medlior
• Sang Mi Lee, Director of Innovative Access Solutions, MORSE Consulting
• Jaclyn Beca, Director of Pharmacoeconomics and RWE, MORSE Consulting

Medlior and MORSE Consulting are pleased to offer a workshop dedicated to the reimbursement considerations for drugs for oncology indications.

The workshop will be tailored for market access teams working on oncology assets to understand the best practices for generating and/or leveraging real-world evidence (RWE) to support payer negotiations and potential outcomes-based agreements (OBAs) in Canada.

The specific topics for the workshop include:

• Navigating the Landscape: Understanding possibilities for OBAs for oncology drugs, including Project Orbis and drugs without OS data, and characteristics of a product and indication best suited for successful OBAs in Canada
• Data-Driven Success: How to assess your RWE needs for HTA and negotiations
• Canadian Requirements: Identifying Canadian RWE sources, processes, and requirements for accessing and generating necessary data
• Strategic Planning: Building an RWE strategy that serves multiple purposes across market access
• Leveraging Patient Support Programs: Effective strategies for partnership and success

The 2-hour workshops will be held virtually and led by senior staff from MORSE and Medlior. All participants will receive a comprehensive PDF of the workshop content, as well as Q&A notes that could serve as a future reference.

Contact us at for more information on pricing and availability.

• Tara Cowling, President and Managing Principal, Medlior
• Suzanne McMullen, Senior Principal, Medlior
• Sang Mi Lee, Director of Innovative Access Solutions, MORSE Consulting
• Jaclyn Beca, Director of Pharmacoeconomics and RWE, MORSE Consulting

The workshop is 2 hours and led by Tara Cowling, Founder and President of Medlior, and Eileen Shaw, Principal of RWE at Medlior. The workshop will be hosted by Medlior on the Zoom platform. Organizational attendance is limited to 100 attendees. The cost for the workshop is $6400 CAD. After the meeting, a PDF copy of the presentation slide deck along with Q&A meeting notes will be provided.

The workshop is 3-hours and is led by Tara Cowling, Founder and President of Medlior, and Dr Ahmed Abou-Setta, Director of Knowledge Synthesis, George and Fay Yee Centre for Healthcare Innovation (University of Manitoba) and Manitoba SPOR SUPPORT Unit. The workshop will be hosted by Medlior on the Zoom platform. Organizational attendance is limited to 100 attendees. The cost for the workshop is $6400 CAD. After the meeting, a PDF copy of the presentation slide deck along with Q&A meeting notes will be provided.